Bryan G. Morton, a biopharmaceutical industry veteran, has been appointed non-executive chairman of Oxford BioTherapeutics Ltd, which is developing antibody therapies for cancer. Mr Morton was previously chief executive of EUSA Pharma Inc, a specialty oncology company that was acquired by Jazz Pharmaceuticals Plc in 2012. Prior to this, he was CEO of Zeneus Pharma Ltd, a specialty oncology and critical care company that was acquired by Cephalon Inc in 2005.
Oxford BioTherapeutics announced the appointment on 26 June 2013.
Copyright 2013 Evernow Publishing Ltd